Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Cash from Operations (2022 - 2024)

Adial Pharmaceuticals' Cash from Operations history spans 3 years, with the latest figure at 1453821.0 for Q4 2024.

  • For Q4 2024, Cash from Operations rose 34.17% year-over-year to 1453821.0; the TTM value through Dec 2024 reached 6922306.0, down 1.7%, while the annual FY2025 figure was 6492603.0, 6.21% up from the prior year.
  • Cash from Operations for Q4 2024 was 1453821.0 at Adial Pharmaceuticals, up from 1694096.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1158290.0 in Q3 2022 and bottomed at 3534391.0 in Q2 2022.
  • The 3-year median for Cash from Operations is 1647833.5 (2023), against an average of 1860248.42.
  • The largest YoY upside for Cash from Operations was 52.77% in 2023 against a maximum downside of 57.25% in 2023.
  • A 3-year view of Cash from Operations shows it stood at 1404432.0 in 2022, then plummeted by 57.25% to 2208411.0 in 2023, then soared by 34.17% to 1453821.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Cash from Operations are 1453821.0 (Q4 2024), 1694096.0 (Q3 2024), and 2148153.0 (Q2 2024).